The Wall Street Journal, June 30, 2014

Anne Wojcicki, chief executive of 23andMe, is determined to overturn the way traditional health care works in the U.S. It hasn't been easy. Last year, the Food and Drug Administration shut down sales of her genetics company's personalized health reports—one of its main sources of revenue. But Ms. Wojcicki (pronounced wo-JIT-ski) isn't backing down. It has been more than six years since 23andMe's splashy appearance at the World Economic Forum in Davos, Switzerland. On their way out of the annual Google party at 3 a.m., heads of state and CEOs stumbled down the hallways of the Steigenberger Belvédère Hotel to be greeted by lines of 23andMe's "spit coaches." [Subscription Required]

Facebook icon
LinkedIn icon
Twitter icon